Involution of infantile haemangiomas after imiquimod 5% cream

Clinical and Experimental Dermatology

Volumn 33, Issue 4, 2008, Pages 446-449

  Barry, R B M ^a   Hughes, B R ^a   Cook, L J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FEVER; HEMANGIOMA; HUMAN; INFANT; INFLAMMATION; INVOLUTION; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN BLEEDING; SKIN ULCER;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; FEMALE; HEMANGIOMA; HUMANS; INFANT; MALE; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 45149099011     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02676.x     Document Type: Article

References (11)

1. Greig AV, Harris DL. A study of perceptions of facial haemangiomas in professionals involved in child abuse surveillance. Pediatr Dermatol 2003 20 : 1 4.
2. Martinez MI, Sanchez-Carpintero I, North PE et al. Infantile haemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002 138 : 881 3.
3. Welsh O, Olazaran Z, Gomez M et al. Treatment of infantile haemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004 51 : 639 42.
4. Hazen PG, Carney JF, Engstrom CW et al. Proliferating haemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 2005 22 : 254 6.
5. Takahashi K, Mulliken JB, Kozakewich HP et al. Cellular markers that distinguish the phases of haemangioma during infancy and childhood. J Invest Clin 1994 93 : 2357 64.
6. Sidbury R, Neuschler N, Neuschler E et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003 121 : 1205 9.
7. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000 43 : S6 11.
8. Imbertson LM, Beaurline JM, Couture AM et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998 110 : 734 9.
9. Barlow CF, Priebe CJ, Mulliken JB et al. Spastic diplegia as a complication of interferon alfa-2a treatment of haemangiomas of infancy. J Pediatr 1998 132 : 527 30.
10. Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001 44 : 962 72.
11. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic haemangioma. Plast Reconstr Surg 1999 104 : 1616 23.